A Randomized Clinical Trial of Extended-Release Naltrexone for Probationers and Parolees

• In Event: Improving Outcomes in Correctional Populations

Abstract

Increasing evidence exists for the feasibility and effectiveness of VIVITROL® (naltrexone for extended-release injectable suspension) to treat opioid use disorder among individuals who are under criminal justice supervision. The present study is a randomized clinical trial of VIVITROL provided to male and female probationers/parolees with histories of opioid disorders. Eighty participants were randomized to one of two conditions: 1) VIVITROL for six months (n=39); or 2) Treatment as Usual (n=41). The two study groups were compared at 6-months post-baseline on: treatment retention; opioid positive urine results; self-reported opioid use; self reported criminal activity; and re-arrest and reincarceration.

Authors

• Timothy Kinlock, Friends Research Institute, Inc.

• Michael Gordon, Friends Research Institute, Inc.